Stephen Mahoney compensation by year
Viridian Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $112,847 | $650,000 | $700,000 |
| Bonus | $63,762 | $0 | $0 |
| Stock awards | $0 | $0 | $1,058,098 |
| Option awards | $12,302,728 | $0 | $4,381,713 |
| Non-equity incentive | $0 | $464,750 | $630,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $184 | $2,704 | $6,438 |
| Total | $12,479,521 | $1,117,454 | $6,776,249 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Viridian Therapeutics, Inc. DEF 14A filed April 17, 2026, accession 0001193125-26-160344, and prior-year filings.
How this page was built: the Viridian Therapeutics, Inc. filed document, accession 0001193125-26-160344. Every figure is read from that document and cited to the page and table it appears in. Filed April 17, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 73,428 | $2,285,079 | — |
| Option | 577,225 | — | $13.02 |
| Option | 357,960 | — | $14.41 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Viridian Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Viridian Therapeutics discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $1,050,000 | $5,689,785 | $59,488 | $6,808,273 |
| Resignation for good reason, no change in control | $1,050,000 | $5,689,785 | $59,488 | $6,808,273 |
| Change in control and involuntary termination | $2,240,000 | $18,714,363 | $79,317 | $21,033,680 |
| Change in control and resignation for good reason | $2,240,000 | $18,714,363 | $79,317 | $21,033,680 |
Per the Potential Payments Upon Termination or Change in Control table in Viridian Therapeutics, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Viridian Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Stephen Mahoney · this page | President, Chief Executive Officer | $6,776,249 |
| Radhika Tripuraneni | Chief Medical Officer | $4,080,466 |
| Thomas Beetham | Chief Operating Officer | $3,761,182 |
| Seth Harmon | Chief Financial Officer | $2,642,779 |
| Jennifer Tousignant | Chief Legal Officer | $2,351,915 |
Board service
Viridian Therapeutics board · FY2023–FY2025How this board is paid
Company policy: Viridian Therapeutics pays directors a $40,000 cash retainer and $358,600 in equity. As stated in Viridian Therapeutics's FY2025 proxy.
The full Viridian Therapeutics compensation record
free company briefThis page is one person within Viridian Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Viridian Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Viridian Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Viridian Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.